Conclusions: The CAREGIVERS questionnaire showed to be validated to assess the impact of pediatric rheumatic diseases.

References:

Disclosure of Interests: None declared

**SERUM ALBUMIN LEVELS AND DEPRESSION IN JSLE**

S. Ganhão1, A. Mendes2, F. Aguiar3, M. Rodrigues4, I. Brito2,3, 4Centro Hospitalar e Universitário de São João, Young Adult and Pediatric Rheumatology Unit, Oporto, Portugal; 2Faculty of Medicine of Oporto’s University, Oporto, Portugal; 3Centro Hospitalar e Universitário de São João, Young Adult and Pediatric Rheumatology Unit, Oporto, Portugal; 4Centro Hospitalar e Universitário de São João, Department of Clinical Neurosciences and Mental Health, Oporto, Portugal

**Background:** Albumin is a negative acute phase response protein synthesized in the liver, being an important marker of inflammation. Under inflammatory conditions, the transcapillary escape rate of albumin may increase, leading to hypoalbuminemia. Systemic lupus erythematosus (SLE) is a chronic condition involving multiple organ systems, inducing functional disability and psychological burden responsible for noteworthy depressive symptoms1. Depression may be related with psychosocial, environmental and biological factors, disease activity and severity. Several studies have shown that immune activation and increased concentrations of positive and decreased concentrations of negative factors are involved in the pathogenesis of depression2. As albumin has the capacity to bind homocysteine, lowered serum albumin levels leads to hyperhomocysteinemia, a well-known risk factor for depression. Moreover, hypoalbuminemia decrease the availability of tryptophan, an essential amino acid from which the neurotransmitter serotonin is derived, and induce oxidative stress, which further decreases antioxidant levels in people with depression.

**Objectives:** To assess the association between serum albumin levels and depressive symptoms in juvenile-onset SLE (JSLE) patients.

**Methods:** A cross-sectional sample of JSLE patients, currently aged ≥ 16 years, completed a psychosocial assessment including quality of life (SF-36) anxiety and depressive symptoms (HADS), and serum albumin levels (HMSMME), between October 2018-May 2019. Local Ethics Committee approved the study. All patients fulfilled both 2012 and 2019 EULAR/ACR classification criteria for SLE. Juvenile-onset was defined as age at diagnosis <18 years. Demographics and clinical characteristics were collected. Statistical analysis was performed with SPSS. Variables were compared with spearman correlations tests.

**Results:** 30 JSLE patients were included (90% female) in the study, with median (min-max) age of 21 (16-35) years, with mean (SD) age of diagnosis of 15.8 ± 2.1. Median albumin serum level was 4.17 (16.4-63) g/dL. Psychosocial assessment revealed a mean (SD) score in HADS - Depressive score of 3.9 (3.3), HADS - Anxiety of 9 (4.3), MMSE of 27.7 (18). Physical health SF-36 of 66.8 (9.9) and Mental health SF-36 of 68.9 (175). 23.3 % JSLE showed mild cognitive impairment, 63.3% anxiety and 13.3% depression. We observed significant inverse linear relationships between serum albumin levels and depressive symptoms score (p=0.042, r=0.380) and with anxiety symptoms score (p=0.029, r=0.406). No significant correlations were detected between albumin serum concentrations and cognitive assessment.

**Conclusion:** Our findings are consistent with studies previously reporting the potentially protective effect of high serum albumin levels on mental health in different populations. A possible inflammation related aetiology for depression in JSLE patients is highlighted, further explained through the protective roles played by albumin in inflammation, infection, and oxidative damage.

References:

**LIPID METABOLISM AND DISEASE ACTIVITY IN JSLE PATIENTS**

S. Ganhão1, A. Mendes2, F. Aguiar3, M. Rodrigues4, I. Brito2,3, 4Centro Hospitalar e Universitário de São João, Rheumatology, Oporto, Portugal; 2Faculty of Medicine of Oporto’s University, Oporto, Portugal; 3Centro Hospitalar e Universitário de São João, Young Adult and Pediatric Rheumatology Unit, Oporto, Portugal; 4Centro Hospitalar e Universitário de São João, Department of Clinical Neurosciences and Mental Health, Oporto, Portugal

**Background:** Systemic lupus erythematosus (SLE) is an autoimmune systemic disease associated with premature atherosclerosis. Risk factors include dyslipoproteinemia, inflammation, oxidized low-density lipoprotein (LDL), hyperhomocysteinemia and antiphospholipid antibodies. Hyperlipidemic condition is being reported to promote the production of proinflammatory cytokines such as IL-1β, IL-6, and IL-27 and lowering blood lipid levels improves the disease. Oxidative stress is elevated, mainly due to mitochondrial dysfunction, further disrupting lipid metabolism. Some drugs also have an impact on lipid profile, such as chronic steroid use, which worsens LDL, HDL, and TG levels.

**Objectives:** To assess the relationship between lipid profile and disease activity in juvenile SLE (JSLE) patients.

**Methods:** Retrospective study of JSLE patients, fulfilling both 2012 and 2019 EULAR/ACR classification criteria for SLE. Juvenile-onset was defined as age at diagnosis <18 years. Demographics and clinical characteristics were collected. To evaluate the activity of SLE, the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was used. Statistical analysis was performed with SPSS. Spearman’s rank non-parametric test or Pearson’s parametric test were used to assess the bivariate correlation for inflammatory and metabolic variables. P value <0.05 was considered significant for all the statistical tests.

**Results:** 35 patients were included, with current median (min-max) age of 22 (17-32) years, sex (male/ female) 31.4% / 68.6% and median (SD) disease duration of 15.8 (2.4) years. 51.4% were female. Median ESR was 19 (2-75) mm/h, CRP 1.65 (0.9-19.6) mg/L, albumin 41.6 (17.6-74.3) g/L, proteinuria 0.2 (0-3) g/dL, leukocytocoria 0 (0-1362.7) /L, erythrocytoria 0 (0-501.9) /μL and anti-doubled stranded DNA 89.3 (10-800) /μL. Mean C3 was 102.1 (21.6), C4 17.1 (7.4) mg/dL and creatinine 0.63 (0.1) mg/dL. Median SLEDAI was 2 (0-12). All were ANA positive, 40 % positive for antinucleosomes antibodies, 25.7% anti-ribosomal P protein antibody, 11.4% anti-Sm, 8.6% autoantibodies against β2-glycoprotein I, 8.6% anti-cardiolipin, 14.3% lupus anticoagulant, 37.1% anti-SSA and 6.6% anti-SSB. Articular manifestations were present in 48.6%, mucocutaneous in 77.1%, haematological in 45.7%, lupus nephritis in 42.9%, serositis in 8.6% and pulmonary interstitial disease in 2.9%. Mean (SD) total cholesterol values (TC) was 165.3 (44.7) mg/dL and LDL 94.5 (29.4) mg/dL. Median high-density lipoprotein was 52 (28-92) and triglycerides (TG) 81.5 (41-253) mg/dL. Median daily prednisolone dose was 5 (40) mg. 88.6% were treated with hydroxychloroquine, 31.4% with mycophenolate mofetil and 14.3% with azathioprine. TC was negatively correlated with serum albumin (p=0.043, rho=-0.378) and positively with SLEDAI (p=0.032; rho = 0.392), proteinuria (p=0.009; rho = 0.469) and leukocytocuria (p=0.031; rho=0.394). A positive correlation was found between LDL and proteinuria (p=0.043; rho=0.385) and between TG and CRP (p=0.001; rho=0.575). TG were also positively correlated with prednisolone daily dose (p=0.035; rho=0.394). Mean LDL was higher in anti-Sm positive patients (p=0.022). No differences were found regarding anti-phospholipids antibodies. Nephritic lupus patients had worse lipid metabolism, but this did not reach statistical significance.

**Conclusion:** In our cohort, increased expression of TC, LDL and TGs is associated with disease activity in SLE. As expected, higher doses of prednisolone also correlated with lipid metabolism.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4608